Health ❯ Healthcare ❯ Clinical Trials

Phase 2 Trials

Weight Loss Studies Dostarlimab Protocol Violations Monlunabant Phase 2a Study Vaccine Efficacy Pancreatic Cancer Phase 3 Trials Efficacy Studies BIIB080 2-THE-TOP Trial Drug Efficacy Maridebart Cafraglutide Chemoradiation SWOG S2000 Trial Gastric Cancer Ifinatamab Deruxtecan Antimicrobial Agents AMT-130 WILLOW Trial AMX0035 ImmunoTACE Trial B-cell Acute Lymphoblastic Leukemia TRANSCEND FL Trial Neoadjuvant Therapy eNRGy Trial Combination Therapy TRUST-II Study SunRISe-1 Trial Rezataopt Monotherapy LINKER-SMM1 Trial Silevertinib Trials SAVE Trial Study Results Pembrolizumab Gastroenteropancreatic Neuroendocrine Tumors NOBILITY Trial EPCORE NHL-1 Trial Eli Lilly and Company Nivolumab Study Novo Nordisk BX004 NHS Innovations WILLOW Study KEYNOTE-942/mRNA-4157-P201 Liraglutide Study

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

Next steps center on Phase 3 confirmation, with full data pending.

Amgen Reports Year-Long Weight-Loss Maintenance With Monthly or Quarterly MariTide Dosing

Phase II Trial Finds 24 Gy Preoperative Radiation With Pembrolizumab Boosts T‑Cell Infiltration in HR+/HER2− Breast Cancer

Structure Therapeutics' Oral GLP-1 Posts Up to 15% Placebo-Adjusted Weight Loss as Company Prepares Phase 3

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

FDA Approves Breyanzi for Marginal Zone Lymphoma After Two or More Therapies

Silevertinib Delivers 60% Response and Strong CNS Activity in First-Line NSCLC With Non-Classical EGFR Mutations

FDA Approves Epkinly Monotherapy and Triplet Regimen for Relapsed Follicular Lymphoma

Perioperative Immunotherapy and Liquid Biopsy Show Promise in Resectable Mesothelioma Phase 2 Trial

B7-H3 ADC Ifinatamab Deruxtecan Shows 48% Response in Relapsed ES-SCLC in Phase 2

FDA Approves Brensocatib as First Treatment for Non-Cystic Fibrosis Bronchiectasis

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial

Phase 3 Trial Launches to Test Electric Field and Immunotherapy Combo in Glioblastoma